Abstract

BackgroundRecently, the high-mobility group A1 gene (HMGA1) variant IVS5-13insC has been associated with type 2 diabetes, but reported associations are inconsistent and data are lacking in Hispanic and African American populations. We sought to investigate the HMGA1-diabetes association and to characterize IVS5-13insC allele frequencies and linkage disequilibrium (LD) in 3,070 Caucasian, Hispanic, and African American patients from the INternational VErapamil SR-Trandolapril STudy (INVEST).MethodsINVEST was a randomized, multicenter trial comparing two antihypertensive treatment strategies in an ethnically diverse cohort of hypertensive, coronary artery disease patients. Controls, who were diabetes-free throughout the study, and type 2 diabetes cases, either prevalent or incident, were genotyped for IVS5-13insC using Taqman®, confirmed with Pyrosequencing and Sanger sequencing. For LD analysis, genotyping for eight additional HMGA1 single nucleotide polymorphisms (SNPs) was performed using the Illumina® HumanCVD BeadChip. We used logistic regression to test association of the HMGA1 IVS5-13insC and diabetes, adjusted for age, gender, body mass index, and percentage European, African, and Native American ancestry.ResultsWe observed IVS5-13insC minor allele frequencies consistent with previous literature in Caucasians and African Americans (0.03 in cases and 0.04 in controls for both race/ethnic groups), and higher frequencies in Hispanics (0.07 in cases and 0.07 in controls). The IVS5-13insC was not associated with type 2 diabetes overall (odds ratio 0.98 [0.76-1.26], p=0.88) or in any race/ethnic group. Pairwise LD (r2) of IVS5-13insC and rs9394200, a SNP previously used as a tag SNP for IVS5-13insC, was low (r2=0.47 in Caucasians, r2=0.25 in Hispanics, and r2=0.06 in African Americans). Furthermore, in silico analysis suggested a lack of functional consequences for the IVS5-13insC variant.ConclusionsOur results suggest that IVS5-13insC is not a functional variant and not associated with type 2 diabetes in an ethnically diverse, hypertensive, coronary artery disease population. Larger, more adequately powered studies need to be performed to confirm our findings.Trial registrationclinicaltrials.gov (NCT00133692)

Highlights

  • The high-mobility group A1 gene (HMGA1) variant IVS5-13insC has been associated with type 2 diabetes, but reported associations are inconsistent and data are lacking in Hispanic and African American populations

  • The genomic inflation factor lambda was 1.03 for INternational VErapamil sustained release (SR)-Trandolapril STudy (INVEST) individuals genotyped for the HMGA1 IVS5-13insC variant, suggesting minimal population stratification in genotyped individuals

  • Our results suggest that the HMGA1 IVS5-13insC is not associated with type 2 diabetes and may not have an important functional role in diabetes pathogenesis

Read more

Summary

Introduction

The high-mobility group A1 gene (HMGA1) variant IVS5-13insC has been associated with type 2 diabetes, but reported associations are inconsistent and data are lacking in Hispanic and African American populations. Low frequency variation may account for much of the missing heritability in type 2 diabetes risk and may help translate genetic association study results into clinical type 2 diabetes risk prediction. The low frequency insertion polymorphism IVS5-13insC (c.136-14_136-13insC) in the high-mobility group A1 gene (HMGA1), a transcriptional regulator of the insulin receptor gene (INSR), was identified and associated with type 2 diabetes [5]. Conflicting results for an HMGA1 association with type 2 diabetes and the lack of data in diverse race/ethnic groups make clinical translation of the HMGA1 IVS513insC genotyping especially difficult

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call